Additional file 2: Tables S1a-d. of TP53 hotspot mutations are predictive of survival in primary central nervous system lymphoma patients treated with combination chemotherapy

Full text: Download

Publisher: Unknown publisher

Preprint: policy unknown. Upload

Postprint: policy unknown. Upload

Published version: policy unknown. Upload

Abstract
Clinical data in 107 PCNSL patients and TP53, MIR34A, and DAPK subgroups. Tables S2a-b. Disease status (a), and treatment at relapse/progression (b). Tables S3a-d. Immunohistochemical marker expression in 107 PCNSL patients and TP53, MIR34A, and DAPK subgroups. (PDF 534 kb)